See also this year's filing and all EDGAR filings for this company.
PDF Report 0001851194_2023_Ventyx_Biosciences_Inc.pdf
Logs
| info | Ambiguous roles for statement | input.sec.calculation_linkbase.expand_agg | {'statement': 'operations', 'valid_roles': {'100030 - Statement - Consolidated Statements of Operations and Comprehensive Loss 2': 3, '100050 - Statement - Consolidated Statements of Operations and Comprehensive Loss': 12}} |
| info | Added remainder_ComprehensiveNetIncome directly from 10K | industry.us_generic | {} |
Graph
Absolute values for 0001851194, Ventyx Biosciences Inc.
| xvar | xval | |
|---|---|---|
| 0 | AssetsCurrent | 330,688,000 |
| 1 | IntangibleAssetsNetIncludingGoodwill | 0 |
| 2 | PropertyPlantAndEquipmentNet | 407,000 |
| 3 | remainder_Assets | 40,305,000 |
| 4 | LiabilitiesCurrent | 16,359,000 |
| 5 | LiabilitiesNoncurrent | 1,146,000 |
| 6 | remainder_Liabilities | 0 |
| 7 | CostOfGoodsAndServicesSold | 0 |
| 8 | SellingGeneralAndAdministrativeExpense | 25,398,000 |
| 9 | ResearchAndDevelopmentExpense | 87,738,000 |
| 10 | remainder_Expenses | 0 |
| 11 | remainder_Revenues | 0 |
| 12 | remainder_NetIncome | 4,710,000 |
| 13 | remainder_ComprehensiveNetIncome | -1,065,000 |
| yvar | yval | |
|---|---|---|
| 0 | Assets | 371,400,000 |
| 1 | Liabilities | 17,505,000 |
| 2 | Expenses | 113,136,000 |
| 3 | Revenues | 0 |
| 4 | StockholdersEquity | 353,895,000 |
| 5 | NetIncome | -108,426,000 |
| 6 | ComprehensiveNetIncome | -108,958,500 |
| 7 | BaseVar | 253,908,000 |
| 8 | EconomicCapitalRatio | 2.57 |
Edgar->Model Mapping
Feature Distribution
Change over Time
